TREM2 and Alzheimer disease: Given all the above, biomarkers of microglia activation have been evaluated for diagnosing and monitoring AD, with some attracting more attention, including the CX3 chemokine ligand 1 (CX3CL1), triggering receptors expressed in myeloid cells 2 (TREM2), and some metalloproteinases.